Press release BoxID: 662256 (SIRION BIOTECH GmbH)
  • Am Klopferspitz 19
  • 82152 Martinsried
  • Contact person
  • Dieter Lingelbach
  • +49 (89) 12017222

SIRION Biotech presents at SACHS Forum in Zurich

Investment opportunities with viral vector technologies

(PresseBox) (Martinsried, ) SACHS Associates is holding its 7th Annual European Life Science CEO Forum for Partnering & Investing at the Zurich airport. SIRION Biotech is to present investment opportunities with viral vectors for gene studies, gene therapy and vaccines.

Website Promotion


SIRION Biotech started in Munich in 2007 with the idea of enabling novel cell models closer to reality than ever before. This required the assembly of an all-encompassing, novel viral vector platform. Both, designing de novo viral vectors and the subsequent creation of custom cell models will pave the way for superior compound development in the life sciences. SIRION's technologies have been validated in over 300 single projects with more than 100 academic and industrial partners. As a result, cell models for drug discovery and development have become highly reliable, as have the use of new viral vectors in gene therapy and vaccine studies.